|
- Time-Dependent Apparent Increase in dd-cfDNA . . . - Oxford Academic
Monitoring of dd-cfDNA has been validated in several clinical trials with somewhat different or even conflicting results in terms of diagnostic performance and threshold values used to distinguish KTx recipients with a healthy graft from those with graft damage (e g , rejections)
- Time-Dependent Apparent Increase in dd-cfDNA Percentage in . . . - PubMed
Conclusions: The time-dependent decrease of host cfDNA resulted in an apparent increase of dd-cfDNA fraction in stable KTx patients For long-term surveillance, measurement of absolute dd-cfDNA concentrations appears to be superior to percentages to minimize false positive results
- Volume 66 Issue 10 | Clinical Chemistry | Oxford Academic
Genomic Prediction of Antimicrobial Resistance: Ready or Not, Here It Comes! Eric M Ransom and others Clinical Chemistry, Volume 66, Issue 10, October 2020, Pages 1278–1289, https: doi org 10 1093 clinchem hvaa172 Ekkehard Schütz and others
- Volume 66 Issue 9 | Clinical Chemistry | Oxford Academic
This issue of Clinical Chemistry contains a research study that focuses on a machine learning approach for the automated interpretation of plasma amino acid profiles
- Clinical Chemistry | Oxford Academic
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
- (PDF) Revisited: Therapeutic and toxic blood concentrations of more . . .
In order to assess the significance of drug substance levels measured in intensive care medicine and clinical and forensic toxicology as well as for therapeutic drug monitoring, it is essential
- Selumetinib in Children with Inoperable Plexiform Neurofibromas.
We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit
- Transplantation Publish Ahead of Print DOI: 10. 1097 TP . . . - ResearchGate
Uwe Schulz reports grants from Novartis, during the conduct of the study; personal fees from Novartis, personal fees from Astellas, personal fees from Sanofi, grants from Actelion, outside
|
|
|